(19)
(11) EP 3 323 815 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
30.12.2020 Bulletin 2020/53

(45) Mention of the grant of the patent:
07.10.2020 Bulletin 2020/41

(21) Application number: 17191765.1

(22) Date of filing: 27.06.2007
(51) International Patent Classification (IPC): 
C07D 277/28(2006.01)
C07D 417/12(2006.01)
A61K 31/425(2006.01)
 C07D 417/04(2006.01)
C07D 417/14(2006.01)
A61P 35/00(2006.01)

(54)

HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE

HUMANE PROTEINTYROSINPHOSPHATASEINHIBITOREN UND IHRE VERWENDUNG

INHIBITEURS DE PROTÉINES TYROSINE-PHOSPHATASES HUMAINES ET LEUR UTILISATION

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

(30) Priority: 27.06.2006 US 816730 P

(43) Date of publication of application:
23.05.2018 Bulletin 2018/21

(60) Divisional application:
20200440.4

(62) Application number of the earlier application in accordance with Art. 76 EPC:
12196174.2 / 2592072
07809907.4 / 2041102

(73) Proprietor: Aerpio Pharmaceuticals, Inc.
Cincinnati, OH 45242 (US)

(72) Inventors:
  • GRAY, Jeffrey Lyle
    Loveland OH Ohio 45140 (US)
  • CLARK, Cynthia Monesa
    Concord MA Massachusetts 01742 (US)
  • AMARASINGHE, Kande K.D.
    Ellicot City MD Maryland 21042 (US)
  • MAIER, Matthew Brian
    Chesapeake, VA 23321 (US)
  • NICHOLS, Ryan
    Cincinnati OH Ohio 45212 (US)

(74) Representative: Avidity IP 
Broers Building Hauser Forum 21 JJ Thomson Avenue
Cambridge CB3 0FA
Cambridge CB3 0FA (GB)


(56) References cited: : 
US-A1- 2004 167 183
 US-B1- 6 596 772
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).